 Cynthia Firnhaber
Concepts (274)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Dysplasia | 15 | 2022 | 38 | 6.410 |
Why?
| | Uterine Cervical Neoplasms | 19 | 2022 | 216 | 5.710 |
Why?
| | HIV Infections | 45 | 2022 | 2459 | 4.500 |
Why?
| | Papillomavirus Infections | 17 | 2022 | 265 | 4.320 |
Why?
| | South Africa | 40 | 2021 | 163 | 3.460 |
Why?
| | Papillomaviridae | 11 | 2022 | 101 | 2.800 |
Why?
| | HIV Seropositivity | 8 | 2017 | 111 | 1.790 |
Why?
| | Alphapapillomavirus | 2 | 2022 | 38 | 1.670 |
Why?
| | Papillomavirus Vaccines | 5 | 2021 | 221 | 1.640 |
Why?
| | Early Detection of Cancer | 7 | 2022 | 360 | 1.600 |
Why?
| | Tuberculosis, Multidrug-Resistant | 9 | 2019 | 45 | 1.540 |
Why?
| | Acquired Immunodeficiency Syndrome | 4 | 2022 | 224 | 1.290 |
Why?
| | Antiretroviral Therapy, Highly Active | 7 | 2020 | 260 | 1.260 |
Why?
| | Cryotherapy | 2 | 2017 | 17 | 1.230 |
Why?
| | Rifampin | 9 | 2021 | 69 | 1.190 |
Why?
| | Quality Assurance, Health Care | 5 | 2017 | 325 | 1.170 |
Why?
| | Colposcopy | 3 | 2015 | 17 | 1.150 |
Why?
| | Breast Neoplasms | 4 | 2019 | 1965 | 1.130 |
Why?
| | Papanicolaou Test | 6 | 2018 | 40 | 1.050 |
Why?
| | Antitubercular Agents | 7 | 2021 | 163 | 1.020 |
Why?
| | HIV-1 | 12 | 2020 | 776 | 1.000 |
Why?
| | Optical Imaging | 2 | 2015 | 56 | 1.000 |
Why?
| | Vaginal Smears | 4 | 2022 | 49 | 0.940 |
Why?
| | Anti-HIV Agents | 12 | 2020 | 664 | 0.930 |
Why?
| | Adult | 47 | 2022 | 31512 | 0.830 |
Why?
| | Delayed Diagnosis | 2 | 2019 | 79 | 0.820 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2017 | 95 | 0.770 |
Why?
| | Antibiotics, Antitubercular | 3 | 2019 | 35 | 0.770 |
Why?
| | Female | 58 | 2022 | 61564 | 0.730 |
Why?
| | Cost-Benefit Analysis | 5 | 2018 | 554 | 0.670 |
Why?
| | CD4 Lymphocyte Count | 11 | 2018 | 267 | 0.660 |
Why?
| | Hepatitis B | 2 | 2008 | 52 | 0.640 |
Why?
| | Breast | 1 | 2018 | 140 | 0.640 |
Why?
| | Antibodies, Viral | 4 | 2018 | 542 | 0.630 |
Why?
| | Access to Information | 1 | 2018 | 53 | 0.630 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2018 | 91 | 0.630 |
Why?
| | Contraceptive Agents, Female | 2 | 2020 | 65 | 0.630 |
Why?
| | Oncology Service, Hospital | 1 | 2017 | 14 | 0.600 |
Why?
| | Prevalence | 13 | 2018 | 2326 | 0.600 |
Why?
| | Electrosurgery | 1 | 2017 | 45 | 0.580 |
Why?
| | Ambulatory Care Facilities | 2 | 2017 | 218 | 0.580 |
Why?
| | Anus Neoplasms | 2 | 2015 | 24 | 0.570 |
Why?
| | Trichomonas vaginalis | 2 | 2012 | 9 | 0.550 |
Why?
| | Tuberculosis | 5 | 2021 | 240 | 0.550 |
Why?
| | Humans | 65 | 2022 | 118972 | 0.540 |
Why?
| | Surgical Instruments | 1 | 2015 | 49 | 0.530 |
Why?
| | Health Resources | 1 | 2017 | 132 | 0.530 |
Why?
| | Mobile Health Units | 1 | 2015 | 16 | 0.520 |
Why?
| | Health Services Accessibility | 2 | 2019 | 781 | 0.520 |
Why?
| | Women's Health Services | 1 | 2015 | 16 | 0.520 |
Why?
| | Viral Load | 8 | 2020 | 419 | 0.510 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2015 | 81 | 0.510 |
Why?
| | Specimen Handling | 1 | 2015 | 165 | 0.500 |
Why?
| | Rural Health Services | 1 | 2015 | 93 | 0.490 |
Why?
| | Precancerous Conditions | 4 | 2020 | 160 | 0.490 |
Why?
| | Middle Aged | 25 | 2019 | 27617 | 0.490 |
Why?
| | Urban Population | 3 | 2018 | 409 | 0.470 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 687 | 0.450 |
Why?
| | Genital Neoplasms, Male | 1 | 2012 | 6 | 0.440 |
Why?
| | Mycoplasma genitalium | 1 | 2012 | 1 | 0.440 |
Why?
| | Urethritis | 1 | 2012 | 2 | 0.440 |
Why?
| | Anti-Retroviral Agents | 5 | 2021 | 208 | 0.440 |
Why?
| | Uterine Cervicitis | 1 | 2012 | 6 | 0.440 |
Why?
| | Neisseria gonorrhoeae | 1 | 2012 | 20 | 0.430 |
Why?
| | Chlamydia trachomatis | 1 | 2012 | 36 | 0.430 |
Why?
| | HIV | 3 | 2022 | 210 | 0.430 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2008 | 19 | 0.420 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 296 | 0.420 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2012 | 51 | 0.420 |
Why?
| | Genital Neoplasms, Female | 1 | 2012 | 72 | 0.400 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2012 | 113 | 0.400 |
Why?
| | Sensitivity and Specificity | 7 | 2017 | 1795 | 0.400 |
Why?
| | Condylomata Acuminata | 1 | 2011 | 7 | 0.400 |
Why?
| | Penile Diseases | 1 | 2011 | 5 | 0.400 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2017 | 610 | 0.390 |
Why?
| | Mass Screening | 5 | 2022 | 1052 | 0.390 |
Why?
| | Protease Inhibitors | 1 | 2011 | 102 | 0.380 |
Why?
| | Coinfection | 5 | 2018 | 119 | 0.370 |
Why?
| | Neutropenia | 1 | 2010 | 133 | 0.360 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1185 | 0.360 |
Why?
| | Anemia | 1 | 2010 | 146 | 0.350 |
Why?
| | Cervix Uteri | 2 | 2019 | 48 | 0.340 |
Why?
| | Thrombocytopenia | 1 | 2010 | 185 | 0.330 |
Why?
| | Diarylquinolines | 2 | 2018 | 5 | 0.330 |
Why?
| | Health Care Costs | 4 | 2018 | 394 | 0.310 |
Why?
| | Delivery of Health Care | 1 | 2015 | 867 | 0.310 |
Why?
| | Women's Health | 1 | 2009 | 274 | 0.300 |
Why?
| | Anal Canal | 2 | 2018 | 83 | 0.300 |
Why?
| | Young Adult | 15 | 2018 | 10793 | 0.300 |
Why?
| | Disease Progression | 4 | 2016 | 2490 | 0.290 |
Why?
| | DNA, Viral | 3 | 2018 | 356 | 0.290 |
Why?
| | Human Papillomavirus DNA Tests | 2 | 2017 | 3 | 0.280 |
Why?
| | Acetic Acid | 2 | 2016 | 17 | 0.270 |
Why?
| | Atazanavir Sulfate | 2 | 2016 | 41 | 0.270 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 1974 | 0.270 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1223 | 0.260 |
Why?
| | Adolescent | 13 | 2022 | 18480 | 0.260 |
Why?
| | Prospective Studies | 7 | 2019 | 6471 | 0.260 |
Why?
| | Tenofovir | 2 | 2017 | 200 | 0.260 |
Why?
| | Medroxyprogesterone Acetate | 2 | 2021 | 30 | 0.250 |
Why?
| | Health Status | 1 | 2009 | 726 | 0.250 |
Why?
| | Developing Countries | 4 | 2018 | 255 | 0.250 |
Why?
| | Drug Resistance, Bacterial | 2 | 2016 | 155 | 0.240 |
Why?
| | Laboratories | 2 | 2015 | 97 | 0.240 |
Why?
| | Treatment Outcome | 9 | 2018 | 9342 | 0.240 |
Why?
| | Lamivudine | 2 | 2015 | 59 | 0.230 |
Why?
| | Zidovudine | 2 | 2015 | 77 | 0.230 |
Why?
| | Male | 22 | 2019 | 57801 | 0.230 |
Why?
| | Comorbidity | 3 | 2016 | 1527 | 0.220 |
Why?
| | Vaccination | 3 | 2021 | 1222 | 0.210 |
Why?
| | Retrospective Studies | 8 | 2021 | 12978 | 0.210 |
Why?
| | Aged | 8 | 2019 | 19657 | 0.210 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2021 | 5 | 0.210 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2021 | 17 | 0.200 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 2 | 2018 | 15 | 0.200 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2021 | 60 | 0.200 |
Why?
| | Risk Factors | 7 | 2017 | 9000 | 0.190 |
Why?
| | Human papillomavirus 18 | 2 | 2011 | 14 | 0.190 |
Why?
| | Human papillomavirus 16 | 2 | 2011 | 25 | 0.190 |
Why?
| | Glycomics | 1 | 2020 | 8 | 0.190 |
Why?
| | Mycobacterium tuberculosis | 3 | 2019 | 266 | 0.190 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 3 | 2018 | 245 | 0.190 |
Why?
| | Incidence | 4 | 2017 | 2424 | 0.180 |
Why?
| | Benzoxazines | 2 | 2021 | 28 | 0.180 |
Why?
| | Cyclopropanes | 2 | 2021 | 80 | 0.180 |
Why?
| | Nucleic Acid Amplification Techniques | 2 | 2019 | 38 | 0.180 |
Why?
| | Alkynes | 2 | 2021 | 56 | 0.180 |
Why?
| | Lopinavir | 3 | 2021 | 29 | 0.180 |
Why?
| | Africa | 3 | 2020 | 100 | 0.180 |
Why?
| | Africa, Southern | 2 | 2016 | 8 | 0.170 |
Why?
| | Ritonavir | 3 | 2021 | 70 | 0.170 |
Why?
| | Drug Combinations | 2 | 2021 | 291 | 0.170 |
Why?
| | Urban Health Services | 1 | 2019 | 60 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 900 | 0.170 |
Why?
| | Brazil | 3 | 2016 | 109 | 0.160 |
Why?
| | South America | 3 | 2016 | 56 | 0.160 |
Why?
| | Anus Diseases | 1 | 2017 | 8 | 0.160 |
Why?
| | Uterus | 1 | 2018 | 194 | 0.150 |
Why?
| | Income | 1 | 2018 | 173 | 0.150 |
Why?
| | Herpesvirus 2, Human | 1 | 2017 | 28 | 0.150 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2012 | 984 | 0.150 |
Why?
| | Health Care Surveys | 1 | 2019 | 546 | 0.150 |
Why?
| | Cross-Sectional Studies | 5 | 2019 | 4552 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 119 | 0.140 |
Why?
| | Cost of Illness | 1 | 2018 | 258 | 0.140 |
Why?
| | Herpes Simplex | 1 | 2017 | 90 | 0.140 |
Why?
| | Atypical Squamous Cells of the Cervix | 1 | 2016 | 1 | 0.140 |
Why?
| | Neoplasm Grading | 1 | 2017 | 258 | 0.140 |
Why?
| | Cytisus | 1 | 2015 | 1 | 0.140 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2513 | 0.140 |
Why?
| | Sex Factors | 3 | 2018 | 1781 | 0.140 |
Why?
| | Mental Status and Dementia Tests | 1 | 2016 | 21 | 0.140 |
Why?
| | Menopause | 1 | 2018 | 266 | 0.140 |
Why?
| | Sputum | 2 | 2016 | 290 | 0.130 |
Why?
| | Staining and Labeling | 1 | 2016 | 146 | 0.130 |
Why?
| | Asia | 2 | 2016 | 54 | 0.130 |
Why?
| | Stavudine | 2 | 2012 | 8 | 0.130 |
Why?
| | Antibodies, Neutralizing | 2 | 2018 | 228 | 0.130 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2016 | 112 | 0.130 |
Why?
| | Pharmacogenetics | 1 | 2016 | 151 | 0.130 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1129 | 0.130 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2017 | 174 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 969 | 0.120 |
Why?
| | Contraception | 1 | 2016 | 118 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2018 | 556 | 0.120 |
Why?
| | Emtricitabine | 1 | 2015 | 146 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 202 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2016 | 254 | 0.120 |
Why?
| | Gene Expression | 1 | 2019 | 1489 | 0.120 |
Why?
| | Markov Chains | 3 | 2018 | 118 | 0.120 |
Why?
| | Bacteriological Techniques | 1 | 2014 | 66 | 0.120 |
Why?
| | RNA, Viral | 2 | 2020 | 572 | 0.110 |
Why?
| | Sexually Transmitted Diseases | 1 | 2015 | 155 | 0.110 |
Why?
| | Trichomonas Vaginitis | 1 | 2012 | 2 | 0.110 |
Why?
| | Time Factors | 4 | 2018 | 6412 | 0.110 |
Why?
| | Antiprotozoal Agents | 1 | 2012 | 12 | 0.110 |
Why?
| | Metronidazole | 1 | 2012 | 21 | 0.110 |
Why?
| | Virus Shedding | 1 | 2012 | 41 | 0.110 |
Why?
| | Age Factors | 3 | 2018 | 2995 | 0.110 |
Why?
| | Mycobacterium | 1 | 2014 | 103 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4596 | 0.110 |
Why?
| | United States | 6 | 2016 | 12555 | 0.100 |
Why?
| | Demography | 1 | 2013 | 274 | 0.100 |
Why?
| | Human papillomavirus 6 | 1 | 2011 | 3 | 0.100 |
Why?
| | Botswana | 1 | 2011 | 8 | 0.100 |
Why?
| | Human papillomavirus 11 | 1 | 2011 | 3 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 693 | 0.100 |
Why?
| | Internationality | 1 | 2012 | 152 | 0.100 |
Why?
| | Vaginosis, Bacterial | 1 | 2011 | 13 | 0.100 |
Why?
| | Antigens, Viral | 1 | 2012 | 181 | 0.100 |
Why?
| | Immunity, Humoral | 1 | 2012 | 117 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2017 | 654 | 0.100 |
Why?
| | Molecular Typing | 1 | 2011 | 18 | 0.100 |
Why?
| | Seroepidemiologic Studies | 1 | 2011 | 146 | 0.100 |
Why?
| | Lipid Metabolism | 2 | 2011 | 477 | 0.100 |
Why?
| | Caribbean Region | 1 | 2010 | 24 | 0.100 |
Why?
| | Americas | 1 | 2010 | 23 | 0.100 |
Why?
| | Sexual Partners | 1 | 2012 | 159 | 0.100 |
Why?
| | Vagina | 1 | 2012 | 148 | 0.100 |
Why?
| | Prognosis | 3 | 2020 | 3443 | 0.090 |
Why?
| | Delayed-Action Preparations | 2 | 2021 | 161 | 0.090 |
Why?
| | Pregnancy | 3 | 2020 | 5690 | 0.090 |
Why?
| | Health Personnel | 1 | 2016 | 588 | 0.090 |
Why?
| | Reflex Sympathetic Dystrophy | 1 | 2009 | 6 | 0.090 |
Why?
| | Autoantigens | 1 | 2012 | 397 | 0.090 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 1012 | 0.090 |
Why?
| | Leptin | 1 | 2010 | 231 | 0.080 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2014 | 334 | 0.080 |
Why?
| | Cognition | 1 | 2016 | 1024 | 0.080 |
Why?
| | Drug Costs | 2 | 2018 | 94 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 4708 | 0.070 |
Why?
| | Adiposity | 1 | 2011 | 516 | 0.070 |
Why?
| | Genotype | 1 | 2011 | 1882 | 0.070 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 736 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2013 | 2874 | 0.060 |
Why?
| | Algorithms | 1 | 2012 | 1541 | 0.060 |
Why?
| | Primary Health Care | 1 | 2015 | 1560 | 0.060 |
Why?
| | Cohort Studies | 4 | 2017 | 5116 | 0.060 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1125 | 0.060 |
Why?
| | Contraceptive Effectiveness | 1 | 2021 | 1 | 0.050 |
Why?
| | Nelfinavir | 1 | 2021 | 8 | 0.050 |
Why?
| | Isoniazid | 1 | 2021 | 53 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1244 | 0.050 |
Why?
| | Liver | 1 | 2008 | 1816 | 0.050 |
Why?
| | Drug Interactions | 1 | 2021 | 352 | 0.050 |
Why?
| | Reference Standards | 1 | 2020 | 176 | 0.050 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 164 | 0.040 |
Why?
| | Risk Assessment | 1 | 2008 | 3057 | 0.040 |
Why?
| | Ethiopia | 1 | 2018 | 35 | 0.040 |
Why?
| | Atrophy | 1 | 2018 | 164 | 0.040 |
Why?
| | Quality-Adjusted Life Years | 1 | 2018 | 103 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 302 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 310 | 0.040 |
Why?
| | Squamous Intraepithelial Lesions of the Cervix | 1 | 2017 | 3 | 0.040 |
Why?
| | Proctoscopy | 1 | 2017 | 6 | 0.040 |
Why?
| | Virus Replication | 1 | 2020 | 405 | 0.040 |
Why?
| | Cytodiagnosis | 1 | 2017 | 27 | 0.040 |
Why?
| | Child | 2 | 2016 | 19129 | 0.040 |
Why?
| | Employment | 1 | 2018 | 135 | 0.040 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 89 | 0.040 |
Why?
| | Seroconversion | 1 | 2017 | 48 | 0.040 |
Why?
| | International Cooperation | 1 | 2017 | 177 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2018 | 313 | 0.040 |
Why?
| | Peru | 1 | 2016 | 59 | 0.030 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 64 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 200 | 0.030 |
Why?
| | Verbal Learning | 1 | 2016 | 74 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2016 | 201 | 0.030 |
Why?
| | DNA, Bacterial | 1 | 2016 | 314 | 0.030 |
Why?
| | Reference Values | 1 | 2016 | 774 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2013 | 57 | 0.030 |
Why?
| | Pathology | 1 | 2013 | 20 | 0.030 |
Why?
| | Educational Status | 1 | 2016 | 437 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1079 | 0.030 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2013 | 115 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2012 | 37 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2016 | 642 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1597 | 0.030 |
Why?
| | Withholding Treatment | 1 | 2012 | 67 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 556 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2016 | 301 | 0.020 |
Why?
| | Serum | 1 | 2011 | 63 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2011 | 229 | 0.020 |
Why?
| | Body Fat Distribution | 1 | 2010 | 45 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 3588 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 965 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 235 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2012 | 1067 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1085 | 0.020 |
Why?
| | Physical Therapy Modalities | 1 | 2009 | 274 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 465 | 0.020 |
Why?
| | Glucose | 1 | 2010 | 953 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 3457 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3174 | 0.010 |
Why?
|
|
Firnhaber's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|